GW Pharmaceuticals PLC- (GWPH) Receives $149.61 Consensus Target Price from Analysts

GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been assigned an average rating of “Buy” from the twelve ratings firms that are covering the firm. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $149.61.

GWPH has been the subject of a number of research reports. Goldman Sachs Group Inc initiated coverage on shares of GW Pharmaceuticals PLC- in a research report on Friday, January 13th. They set a “buy” rating and a $189.00 target price for the company. TheStreet upgraded shares of GW Pharmaceuticals PLC- from a “d+” rating to a “c-” rating in a research report on Tuesday, March 14th. Piper Jaffray Companies set a $147.00 target price on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Tuesday, February 7th. Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Tuesday, February 7th. Finally, Cowen and Company set a $135.00 target price on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Monday, February 6th.

Several institutional investors have recently bought and sold shares of GWPH. Capital Research Global Investors raised its position in GW Pharmaceuticals PLC- by 14.9% in the third quarter. Capital Research Global Investors now owns 3,017,604 shares of the biopharmaceutical company’s stock worth $400,527,000 after buying an additional 390,930 shares in the last quarter. Prudential PLC raised its position in GW Pharmaceuticals PLC- by 75.8% in the fourth quarter. Prudential PLC now owns 2,050,212 shares of the biopharmaceutical company’s stock worth $229,111,000 after buying an additional 884,106 shares in the last quarter. Scopia Capital Management LP purchased a new position in GW Pharmaceuticals PLC- during the third quarter worth $250,218,000. Capital World Investors raised its position in GW Pharmaceuticals PLC- by 74.1% in the third quarter. Capital World Investors now owns 760,800 shares of the biopharmaceutical company’s stock worth $100,981,000 after buying an additional 323,700 shares in the last quarter. Finally, Redmile Group LLC purchased a new position in GW Pharmaceuticals PLC- during the third quarter worth $72,460,000. 72.30% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “GW Pharmaceuticals PLC- (GWPH) Receives $149.61 Consensus Target Price from Analysts” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.wkrb13.com/markets/2065150/gw-pharmaceuticals-plc-gwph-receives-149-61-consensus-target-price-from-analysts.html.

Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded down 0.0612% on Monday, hitting $116.1189. 156,392 shares of the company’s stock were exchanged. GW Pharmaceuticals PLC- has a 12-month low of $74.05 and a 12-month high of $137.88. The company’s 50-day moving average price is $121.66 and its 200 day moving average price is $121.13. The stock’s market cap is $2.93 billion.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its earnings results on Tuesday, February 7th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.58. The company earned $2.54 million during the quarter, compared to analysts’ expectations of $1.85 million. GW Pharmaceuticals PLC- had a negative net margin of 702.90% and a negative return on equity of 20.07%. The firm’s quarterly revenue was down 32.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.06) earnings per share. On average, equities analysts predict that GW Pharmaceuticals PLC- will post ($5.06) earnings per share for the current fiscal year.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

5 Day Chart for NASDAQ:GWPH

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065150/gw-pharmaceuticals-plc-gwph-receives-149-61-consensus-target-price-from-analysts.html

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.